Press Releases Purple Biotech Ltd

Equities

PPBT

IL0007650166

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:15 2024-07-11 am EDT			5-day change	1st Jan Change
16.3 ^ILa	+4.49%		+5.16%	-48.90%

Jun. 27	Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	MT
Jun. 27	Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Purple Biotech : Immediate report on other matter	Jul. 02	PU
Purple Biotech : Immediate Report	Jul. 02	PU
Purple Biotech : Immediate Report	Jul. 02	PU
Purple Biotech : Report Of Foreign Private Issuer Form 6 K	Jul. 02	PU
Purple Biotech : Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit	Jun. 27	PU
Purple Biotech : Immediate Report of Meeting	Jun. 26	PU
Purple Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS Form 6 K	Jun. 26	PU
6K: The Tel Aviv District Court dismissed the previously disclosed lawsuit and motion to approve the lawsuit as a class action lawsuit which was filed against us, our executive directors and certain of our present and former directors in February 2017	Jun. 20	PU
Purple Biotech : Immediate Report	Jun. 05	PU
Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer	Jun. 01	AQ
Purple Biotech Reports First Quarter 2024 Financial Results	May. 21	AQ
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024	Mar. 28	AQ
Purple Biotech : Immediate Report	Mar. 06	PU
6K:Fourth Quarter and Full-Year 2023 Financial Results	Mar. 05	PU
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results	Mar. 05	AQ
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024	Feb. 27	AQ
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial	Feb. 13	AQ
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial	Dec. 14	AQ
Papillary Thyroid Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 30	AQ
Purple Biotech Reports Third Quarter 2023 Financial Results	Nov. 21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Purple Biotech Ltd

Equities

PPBT

IL0007650166

Press Releases

Filters